Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor Progression

NCT04251169 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

20

Enrollment

OTHER

Sponsor class

Stopped The enrollment was stopped prematurely due to the lack of funding

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Pembrolizumab
DRUG: Paclitaxel

Sponsor

SOLTI Breast Cancer Research Group

Collaborators

[object Object]